Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.
Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).
Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.
Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181